{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:08:43Z","timestamp":1780445323491,"version":"3.54.1"},"reference-count":14,"publisher":"Termedia Sp. z.o.o.","issue":"3","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypereosinophilic syndrome (HES) is a\u00a0group of a\u00a0rare diseases characterized by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a\u00a0humanized, monoclonal antibody against interleukin 5 (IL-5) receptor a, which is expressed on human eosinophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case study<\/jats:title>\n                    <jats:p>Here, we present the case of a\u00a0patient with severe HES in whom treatment with benralizumab, an anti-IL-5 receptor monoclonal antibody, was initiated 6 months ago. Prior to benralizumab administration, the patient was treated with glucocorticoids (GS) and mepolizumab. However, instead of the applied treatment and normal level of peripheral eosinophils the patient presented with fluctuating lower respiratory tract symptoms and recurrent exacerbations of HES.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with benralizumab (30 mg s.c. every 4-6 weeks) was started, resulting in significant improvement of respiratory signs and symptoms, normalization of eosinophil count and significant reduction of the methylprednisolone dose (after 5 doses of benralizumab administration). No substantial side effects have been noted during treatment and 6-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We argue that in the severe and relapsing course of HES, rescue treatment with benralizumab should be taken into account, particularly in cases of relative inefficacy of GS and mepolizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/ceji.2021.108259","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T09:15:01Z","timestamp":1633079701000},"page":"395-397","source":"Crossref","is-referenced-by-count":6,"title":["Severe hypereosinophilic syndrome successfully treated with a\u00a0monoclonal antibody against interleukin 5 receptor \u03b1 \u2013 benralizumab"],"prefix":"10.5114","volume":"46","author":[{"given":"Joanna","family":"Kosa\u0142ka-W\u0119giel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamert","family":"Milewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"And\u017celika","family":"Siwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Strach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ochrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Korkosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"ref-1540639","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang FL","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, et al. (2019): Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med 380: 1336-1346.","journal-title":"N Engl J Med"},{"key":"ref-1540640","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion AD","year":"2015","unstructured":"Klion AD (2015): How I treat hypereosinophilic syndromes. Blood 126: 1069-1077.","journal-title":"Blood"},{"key":"ref-1540641","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib J","year":"2017","unstructured":"Gotlib J (2017): World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92: 1243-1259.","journal-title":"Am J Hematol"},{"key":"ref-1540642","first-page":"30","article-title":"Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab","volume":"25","author":"Kay D","year":"2018","unstructured":"Kay D, Ataya A, Liu X, et al. (2018): Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab. Respir Med Case Rep 25: 30-32.","journal-title":"Respir Med Case Rep"},{"key":"ref-1540643","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12890-020-1134-x","article-title":"Cough in hypereosinophilic syndrome: case report and literature review","volume":"20","author":"Xie J","year":"2020","unstructured":"Xie J, Zhang J, Zhang X, et al. (2020): Cough in hypereosinophilic syndrome: case report and literature review. BMC Pulm Med 20: 90.","journal-title":"BMC Pulm Med"},{"key":"ref-1540644","doi-asserted-by":"crossref","first-page":"381","DOI":"10.12659\/AJCR.912747","article-title":"Hypereosinophilic syndrome in an elderly female: a case report","volume":"20","author":"Khalid F","year":"2019","unstructured":"Khalid F, Holguin F (2019): Hypereosinophilic syndrome in an elderly female: a case report. Am J Case Rep 20: 381-384.","journal-title":"Am J Case Rep"},{"key":"ref-1540645","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald JM","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al. (2016): Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388: 2128-2141.","journal-title":"Lancet"},{"key":"ref-1540646","doi-asserted-by":"crossref","first-page":"e15868","DOI":"10.1097\/MD.0000000000015868","article-title":"Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis","volume":"98","author":"Liu W","year":"2019","unstructured":"Liu W, Ma X, Zhou W (2019): Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis. Med 98: e15868.","journal-title":"Med"},{"key":"ref-1540647","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino NA","year":"2012","unstructured":"Molfino NA, Gossage D, Kolbeck R, et al. (2012): Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 42: 712-737.","journal-title":"Clin Exp Allergy"},{"key":"ref-1540648","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and hematological effects of IL-5(R\u03b1)-targeted therapy: An overview","volume":"73","author":"Hassani M","year":"2018","unstructured":"Hassani M, Koenderman L (2018): Immunological and hematological effects of IL-5(R\u03b1)-targeted therapy: An overview. Allergy 73: 1979-1988.","journal-title":"Allergy"},{"key":"ref-1540649","first-page":"212587","article-title":"Targeting eosinophils: severe asthma and beyond","volume":"8","author":"Caminati M","year":"2019","unstructured":"Caminati M, Menzella F, Guidolin L, et al. (2019): Targeting eosinophils: severe asthma and beyond. Drugs Conte 8: 212587.","journal-title":"Drugs Conte"},{"key":"ref-1540650","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse F","year":"2018","unstructured":"Roufosse F (2018): Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med 5: 49.","journal-title":"Front Med"},{"key":"ref-1540651","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","article-title":"Biologic therapies targeting eosinophils: current status and future prospects","volume":"3","author":"Legrand F","year":"2015","unstructured":"Legrand F, Klion A (2015): Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pr 3: 167-174.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"ref-1540652","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.alit.2019.04.003","article-title":"A case of severe eosinophilic asthma and refractory rheumatoid arthritis well controlled by combination of IL-5R a antibody and TNF a inhibitor","volume":"68","author":"Yamada H","year":"2019","unstructured":"Yamada H, Hida N, Kurashima Y, et al. (2019): A case of severe eosinophilic asthma and refractory rheumatoid arthritis well controlled by combination of IL-5R a antibody and TNF a inhibitor. Allergol Int 68: 536-538.","journal-title":"Allergol Int"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-132113-129699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-132113-129699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:33:47Z","timestamp":1767947627000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Severe-hypereosinophilic-syndrome-successfully-treated-with-a-monoclonal-antibody,132113,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["132113"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2021.108259","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]}}}